B J Maron

Summary

Publications

  1. ncbi Clinical profile of commotio cordis: an under appreciated cause of sudden death in the young during sports and other activities
    B J Maron
    Minneapolis Heart Institute Foundation, Minnesota 55407, USA
    J Cardiovasc Electrophysiol 10:114-20. 1999
  2. ncbi Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations
    B J Maron
    Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minnesota 55407, USA
    J Am Coll Cardiol 38:315-21. 2001
  3. ncbi Clinical course of hypertrophic cardiomyopathy in a regional United States cohort
    B J Maron
    Cardiovascular Research Division, Minneapolis Heart Institute Foundation, School of Public Health, University of Minnesota, 55407, USA
    JAMA 281:650-5. 1999
  4. ncbi Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY)
    B J Maron
    Minneapolis Heart Institute Foundation, Minneapolis, MN 55407, USA
    Circulation 99:2927-33. 1999
  5. ncbi Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy
    B J Maron
    Minneapolis Heart Institute Foundation, MN 55407, USA
    N Engl J Med 342:365-73. 2000
  6. ncbi Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population
    B J Maron
    Minneapolis Heart Institute Foundation, Minneapolis, MN 55407, USA
    Circulation 102:858-64. 2000
  7. ncbi Ventricular arrhythmias, sudden death, and prevention in patients with hypertrophic cardiomyopathy
    B J Maron
    Minneapolis Heart Institute Foundation, 920 E 28th Street, Suite 40, Minneapolis, MN 55407, USA
    Curr Cardiol Rep 2:522-8. 2000
  8. ncbi Assessment of QT dispersion as a prognostic marker for sudden death in a regional nonreferred hypertrophic cardiomyopathy cohort
    B J Maron
    Minneapolis Heart Institute Foundation, Minnesota 55407, USA
    Am J Cardiol 87:114-5, A9. 2001
  9. ncbi Distinguishing hypertrophic cardiomyopathy from athlete's heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening
    B J Maron
    Minneapolis Heart Institute Foundation, 920 East 28th Street, Suite 620, Minneapolis, MN 55407, USA
    Br J Sports Med 43:649-56. 2009

Detail Information

Publications9

  1. ncbi Clinical profile of commotio cordis: an under appreciated cause of sudden death in the young during sports and other activities
    B J Maron
    Minneapolis Heart Institute Foundation, Minnesota 55407, USA
    J Cardiovasc Electrophysiol 10:114-20. 1999
    ....
  2. ncbi Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations
    B J Maron
    Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minnesota 55407, USA
    J Am Coll Cardiol 38:315-21. 2001
    ..We sought to determine whether the development of left ventricular hypertrophy (LVH) can be demonstrated during adulthood in genetically affected relatives with hypertrophic cardiomyopathy (HCM)...
  3. ncbi Clinical course of hypertrophic cardiomyopathy in a regional United States cohort
    B J Maron
    Cardiovascular Research Division, Minneapolis Heart Institute Foundation, School of Public Health, University of Minnesota, 55407, USA
    JAMA 281:650-5. 1999
    ..Hypertrophic cardiomyopathy (HCM) has been regarded as a disease that causes substantial disability, with annual mortality rates of up to 6%, based largely on reports from tertiary referral centers...
  4. ncbi Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY)
    B J Maron
    Minneapolis Heart Institute Foundation, Minneapolis, MN 55407, USA
    Circulation 99:2927-33. 1999
    ..Dual-chamber pacing (DDD) has been proposed as a treatment alternative to surgery for severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), based largely on uncontrolled studies...
  5. ncbi Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy
    B J Maron
    Minneapolis Heart Institute Foundation, MN 55407, USA
    N Engl J Med 342:365-73. 2000
    ..Hypertrophic cardiomyopathy is a genetic disease associated with a risk of ventricular tachyarrhythmias and sudden death, especially in young patients...
  6. ncbi Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population
    B J Maron
    Minneapolis Heart Institute Foundation, Minneapolis, MN 55407, USA
    Circulation 102:858-64. 2000
    ..These data emanated from tertiary HCM centers with highly selected referral patterns skewed toward high-risk patients...
  7. ncbi Ventricular arrhythmias, sudden death, and prevention in patients with hypertrophic cardiomyopathy
    B J Maron
    Minneapolis Heart Institute Foundation, 920 E 28th Street, Suite 40, Minneapolis, MN 55407, USA
    Curr Cardiol Rep 2:522-8. 2000
    ....
  8. ncbi Assessment of QT dispersion as a prognostic marker for sudden death in a regional nonreferred hypertrophic cardiomyopathy cohort
    B J Maron
    Minneapolis Heart Institute Foundation, Minnesota 55407, USA
    Am J Cardiol 87:114-5, A9. 2001
    ..Therefore, QT dispersion would not appear to be useful in devising future risk stratification strategies for predicting sudden death in HC...
  9. ncbi Distinguishing hypertrophic cardiomyopathy from athlete's heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening
    B J Maron
    Minneapolis Heart Institute Foundation, 920 East 28th Street, Suite 620, Minneapolis, MN 55407, USA
    Br J Sports Med 43:649-56. 2009
    ..Consensus criteria and recommendations for eligibility and disqualification of athletes with HCM (and other cardiovascular abnormalities) have proved useful to the practising community...